Eli Lilly, Novo Nordisk prepare to face off in the next obesity drug battleground
1. LLY and Novo Nordisk to launch oral obesity drugs next year. 2. LLY's obesity pill shows lower weight loss than expected in trials. 3. Head-to-head trial results will compare LLY and Novo's oral medications. 4. Analysts reduced 2032 sales estimates for LLY's orforglipron significantly. 5. Future market dynamics for obesity pills remain uncertain, says LLY's leadership.